Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide (AMG 133) Bioavailability Study in Overweight or Obesity
NCT07832799Phase 1Not yet recruiting
- Sponsor
- Amgen
- Start
- Oct 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, randomised, open-label trial of maridebart cafraglutide in obesity (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity, Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07832799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832799.